BACKGROUND: Inhaled interleukin-2 (IL-2) is an effective and safe treatment in metastasing renal cell carcinoma (mRCC) but known to potentially elicit respiratory symptoms. OBJECTIVES: The present study analyses the effects of IL-2 using a panel of measures including markers of airway inflammation. METHODS: Ten patients with mRCC (7m/3f; mean age, 63 yrs) were measured at baseline, 6-10 days after start of therapy (n = 5, inhaled IL-2 only; n = 5, inhaled IL-2 plus 1/11th of daily dose subcutaneously), and 16-29 days later under continuous combined (inhaled plus subcutaneous) therapy, including additional subcutaneous IFN-alpha in 8 patients. RESULTS: After start of therapy median FEV1 declined from 108 to 85 to 90 % predicted and the provocative concentration of methacholine eliciting a 20 % fall in FEV1 (PC20 FEV1) from 16 to 8 to 3 mg/mL, while the level of exhaled nitric oxide (FENO) rose from 27 to 79 to 60 ppb and the percentage of sputum eosinophils from 2 to 18 to 37 % (p<0.01, each), accompanied by cough and dyspnoea (p<0.05). One patient who stopped therapy, was back to baseline values when measured 2 months later. Cytokine production by blood or sputum T lymphocytes was not markedly altered by IL-2 inhalation. CONCLUSIONS: IL-2 inhalation therapy in patients with metastasing renal cell carcinoma is capable of temporarily inducing symptomatic, functional and inflammatory alterations similar to those of bronchial asthma.
BACKGROUND: Inhaled interleukin-2 (IL-2) is an effective and safe treatment in metastasing renal cell carcinoma (mRCC) but known to potentially elicit respiratory symptoms. OBJECTIVES: The present study analyses the effects of IL-2 using a panel of measures including markers of airway inflammation. METHODS: Ten patients with mRCC (7m/3f; mean age, 63 yrs) were measured at baseline, 6-10 days after start of therapy (n = 5, inhaled IL-2 only; n = 5, inhaled IL-2 plus 1/11th of daily dose subcutaneously), and 16-29 days later under continuous combined (inhaled plus subcutaneous) therapy, including additional subcutaneous IFN-alpha in 8 patients. RESULTS: After start of therapy median FEV1 declined from 108 to 85 to 90 % predicted and the provocative concentration of methacholine eliciting a 20 % fall in FEV1 (PC20 FEV1) from 16 to 8 to 3 mg/mL, while the level of exhaled nitric oxide (FENO) rose from 27 to 79 to 60 ppb and the percentage of sputum eosinophils from 2 to 18 to 37 % (p<0.01, each), accompanied by cough and dyspnoea (p<0.05). One patient who stopped therapy, was back to baseline values when measured 2 months later. Cytokine production by blood or sputum T lymphocytes was not markedly altered by IL-2 inhalation. CONCLUSIONS:IL-2 inhalation therapy in patients with metastasing renal cell carcinoma is capable of temporarily inducing symptomatic, functional and inflammatory alterations similar to those of bronchial asthma.
Authors: C Posch; F Weihsengruber; K Bartsch; V Feichtenschlager; M Sanlorenzo; I Vujic; B Monshi; S Ortiz-Urda; K Rappersberger Journal: Br J Cancer Date: 2014-02-11 Impact factor: 7.640
Authors: Eva Verjans; Kim Ohl; Lucy K Reiss; Femke van Wijk; Antonaneta A Toncheva; Anastasia Wiener; Yin Yu; Annette D Rieg; Vincent D Gaertner; Johannes Roth; Edward Knol; Michael Kabesch; Norbert Wagner; Stefan Uhlig; Christian Martin; Klaus Tenbrock Journal: Oncotarget Date: 2015-11-17
Authors: Abdulrahman E Koshak; Nizar M Yousif; Bernd L Fiebich; Emad A Koshak; Michael Heinrich Journal: Front Pharmacol Date: 2018-10-02 Impact factor: 5.810